What is the recommended diagnostic work‑up and treatment for a left breast lump?

Diagnostic Work-Up and Treatment for Left Breast Lump

For a left breast lump, immediately obtain imaging based on age: diagnostic mammography with ultrasound for women ≥30 years, and ultrasound alone for women <30 years, followed by core needle biopsy for any suspicious findings (BI-RADS 4-5). 1, 2

Initial Diagnostic Algorithm

Age-Based Imaging Strategy

Women ≥30 years:

• Start with diagnostic mammography + ultrasound as the primary imaging modality 2, 3
• Bilateral mammography is essential to evaluate both breasts 1
• Ultrasound evaluates both the palpable mass and regional lymph nodes 1

Women <30 years:

• Begin with ultrasound alone (± diagnostic mammography if needed) 2, 3
• Mammography has limited sensitivity in younger women due to dense breast tissue 2
• MRI may be indicated for young patients with dense breast tissue or genetic/familial predisposition 1

Clinical Assessment Requirements

Document these specific findings:

• Complete personal and family medical history, including BRCA mutation risk 1
• Menopausal status 1
• Physical examination of the mass, axilla, and supraclavicular lymph node basins 2
• Laboratory tests: complete blood count, liver and renal function, alkaline phosphatase, and calcium levels 1

Biopsy Decision-Making

When to Biopsy

Proceed immediately to core needle biopsy if: 1, 2

• BI-RADS category 4-5 (suspicious or highly suggestive of malignancy)
• Clinical suspicion remains high despite benign imaging (BI-RADS 1-3)
• Asymmetric thickening or nodularity with high clinical suspicion

Core needle biopsy is mandatory and preferred over fine-needle aspiration because it:

• Provides histological diagnosis of invasive disease 1
• Allows assessment of biomarkers (ER, PgR, HER2, Ki67) 1
• Has superior accuracy compared to FNAC (95.5% diagnostic rate vs 73.2% sensitivity) 4

Pathology Requirements

The pathology report must include: 1

• Histological type and grade
• ER and PgR status
• HER2 status (by IHC or FISH/CISH)
• Proliferation marker (Ki67)
• Place a marker (surgical clip, carbon) into the tumor at biopsy to ensure correct surgical site 1

Management Based on Diagnosis

If Benign (BI-RADS 1-3)

For low clinical suspicion:

• Physical examination every 3-6 months for 1-2 years to assess stability 2
• Return to routine screening 2

For persistent high clinical suspicion despite benign imaging:

• Perform core needle biopsy regardless of imaging findings 2
• Consider consultation with breast specialist 2

If Malignant

Treatment must be delivered by a specialized multidisciplinary team including surgeon, radiation oncologist, medical oncologist, radiologist, pathologist, and breast nurse 1

Locoregional Treatment:

• Breast-conserving surgery (BCS) + whole-breast radiotherapy is preferred for most patients 1, 5
• Sentinel lymph node biopsy (SLNB) is standard for all clinically node-negative (cN0) patients 1, 5
• Mastectomy with reconstruction offered if BCS not feasible 1, 5

Systemic Therapy Decision Algorithm:

The treatment is determined by two factors: 6

1. Endocrine responsiveness (based on ER/PgR status)
2. Risk category (based on tumor size, grade, nodal status, HER2, age)

Risk Categories: 6

• Low risk: Node-negative AND all of: pT ≤2 cm, Grade 1, no vascular invasion, HER2-negative, age ≥35 years
• Intermediate risk: Node-negative with any of: pT >2 cm, Grade 2-3, vascular invasion, HER2-positive, age <35 years
• High risk: Node-positive (1-3 nodes with HER2-positive) OR ≥4 positive nodes

Treatment by Risk and Hormone Status: 6

• Low risk + ER/PgR-positive: Endocrine therapy alone or observation
• Intermediate risk + ER/PgR-positive: Endocrine therapy alone OR chemotherapy followed by endocrine therapy
• High risk + ER/PgR-positive: Chemotherapy followed by endocrine therapy
• Any risk + ER/PgR-negative: Chemotherapy (no endocrine therapy)
• HER2-positive (any risk): Add trastuzumab for 1 year (not for node-negative tumors <1 cm) 6

Endocrine Therapy Specifics: 6

• Premenopausal: Tamoxifen 20 mg/day for 5 years ± ovarian suppression with GnRH analogs
• Postmenopausal: Aromatase inhibitor (anastrozole 1 mg, letrozole 2.5 mg, or exemestane 25 mg daily) at some point—either upfront for 5 years, or after 2-3 years of tamoxifen, or after 5 years of tamoxifen

Chemotherapy Regimens: 6

• Must include anthracycline-based combination (AC, FEC, CEF)
• Add taxane for high-risk patients, especially if ER-negative
• Minimum 4 cycles required

Critical Pitfalls to Avoid

1. Never rely on imaging alone if clinical suspicion is high—always biopsy 2
2. Never use fine-needle aspiration when core needle biopsy is feasible—core biopsy provides superior diagnostic information 1, 4
3. Never give aromatase inhibitors alone to premenopausal patients—they require ovarian suppression or tamoxifen 6
4. Never start tamoxifen concurrently with chemotherapy—begin after chemotherapy completion 6
5. Never give trastuzumab concurrently with anthracyclines—severe cardiotoxicity risk 6
6. Never skip sentinel node biopsy in invasive cancer—it is standard for all cN0 patients 1, 5

Special Considerations

For DCIS (if diagnosed):

• Lumpectomy + whole-breast radiotherapy is standard 7, 5
• SLNB not routinely required unless mastectomy planned or DCIS >5 cm 5
• Consider tamoxifen or AI (postmenopausal) for ER-positive DCIS to reduce recurrence 5

Triple assessment accuracy: When physical examination, imaging, and core biopsy are all positive for malignancy, the positive predictive value is 100% with 95.5% sensitivity 4